About Albumedix
Albumedix is a Healthcare company based in Lyngby (Denmark) founded in 2016, and was acquired by Sartorius in August 2022. Albumin-based products and technologies for biotherapeutics development are provided. The company has 106 employees. Its focus areas include Diversified Pharmaceuticals. Its legal entity is ALBUMEDIX LTD.
Company details
Albumedix was spun-out as a fully owned subsidiary from the Biopharma activities of Novozymes. Albumedix helps biopharmaceutical companies improve patient outcomes with a range of albumin-based products and technologies that facilitate the development of biotherapeutics. Named Recombumin, Albumedixs recombinant albumins are used in the pharmaceutical industry to stabilize drugs and vaccines, extend drug half-life and improve drug delivery (Albumedix offers a first and second generation version of this drug delivery technology under the name Veltis). Their products and technologies are used in clinical and marketed drugs and out-licensed to pharmaceutical and biotech companies. They also use this expertise to strengthen our own drug pipeline. since 2006, Merck has used Albumedixs solutions to produce two vaccines used to treat millions of children worldwide against measles, mumps, rubella and chicken pox. In 2014, Veltis got its commercial breakthrough when GlaxoSmithKline launched a diabetes drug that utilizes the technology, allowing patients to dose weekly instead of daily. In Jan 2016, Albumedix acquired Eleven Therapeutics proprietary Supermin albumin variant assets.
- Headquarters Lyngby, Denmark
- Employees 106
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website albumedix.com
- Social LinkedIn X
- Acquired by Sartorius (Aug 2022)
- Legal Name Albumedix Ltd
Funding Insights of Albumedix
- Total Rounds 1
- Last Round Grant — $335,353
- First Round $335,353
(Sep 2020)
- Investors Count 1
All 1 funding rounds of Albumedix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $335,353 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Albumedix
Albumedix has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Sartorius and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Laboratory and biopharmaceutical equipment is developed for production processes. | 1870 | sartorius.com | Gottingen, Germany |
Investor details for Albumedix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Albumedix
3 dated milestones of Albumedix across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Albumedix is founded.
- Funding First funding round of $335K.
- Exit Acquired by Sartorius.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Albumedix
Complete news archive for Albumedix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Albumedix
Albumedix was founded in 2016 and raised its 1st funding round 4 years after it was founded.
Albumedix is headquartered in Lyngby, Denmark. It is registered at Lyngby, Region Hovedstaden, Denmark.
Albumedix has 106 employees.
Annual revenue of Albumedix is $38.24M as on Dec 31, 2021.
Albumedix was spun-out as a fully owned subsidiary from the Biopharma activities of Novozymes. Albumedix helps biopharmaceutical companies improve patient outcomes with a range of albumin-based products and technologies that facilitate the development of biotherapeutics. Named Recombumin, Albumedixs recombinant albumins are used in the pharmaceutical industry to stabilize drugs and vaccines, extend drug half-life and improve drug delivery (Albumedix offers a first and second generation version of this drug delivery technology under the name Veltis). Their products and technologies are used in clinical and marketed drugs and out-licensed to pharmaceutical and biotech companies. They also use this expertise to strengthen our own drug pipeline. since 2006, Merck has used Albumedixs solutions to produce two vaccines used to treat millions of children worldwide against measles, mumps, rubella and chicken pox. In 2014, Veltis got its commercial breakthrough when GlaxoSmithKline launched a diabetes drug that utilizes the technology, allowing patients to dose weekly instead of daily. In Jan 2016, Albumedix acquired Eleven Therapeutics proprietary Supermin albumin variant assets.
Albumedix has 2 investors. Key investors include Sartorius, and European Union.
Albumedix operates through Albumedix Ltd.
Yes. Albumedix was acquired by Sartorius in August 2022.